Takeda has announced a new partnership with Samsung Bioepis that will see the companies working together to create novel biologic therapies.
The partners will jointly fund and co-develop multiple novel biologic therapies in unmet disease areas, with immediate work to commence on the programme's first therapeutic candidate, TAK-671, which is intended to treat severe acute pancreatitis.
“Takeda and Samsung Bioepis have agreed to collaborate on the development of novel biologic therapies.“
This will leverage Samsung Bioepis' agile biologics development platform and Takeda's best-in-class expertise in drug development, with the overall aim of bringing innovative therapies representing meaningful value to market as efficiently as possible.
It aligns with Takeda's broader strategy of working together with partners who have complementary expertise in order to expand its own drug development capabilities.
Dr Daniel Curran, head of the centre for external innovation at Takeda, said: "By combining our unique capabilities in development and manufacturing along with fresh and innovative clinical approaches, we will maximise the potential for successful introduction of important medicines to patients."
This comes after Takeda formed new partnerships with Stanford University, Shattuck Labs, Molecular Templates and Cardurion Pharmaceuticals in recent weeks.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical